Pfizer cut its dividend to fund the Wyeth deal while facing debt pressure from the Seagen acquisition.
2 reports, 2 independent
Updated Sep 17
Gone quiet
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Pfizer cut its dividend to fund the Wyeth deal while facing debt pressure from the Seagen acquisition.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Pfizer
American multinational pharmaceutical and biotechnology corporation
-
Wyeth
defunct pharmaceutical company
Nothing else this week.
-
Seagen
American biotechnology company
Nothing else this week.
Related events
- Pfizer and Eli Lilly are being discussed as potential dividend investment targets.
- A pricing agreement between Pfizer and the Trump administration helped the company's stock rise.
- Pfizer CEO Ugur Sahin sold shares of the firm's stock.
- Bristol-Myers Squibb and Pfizer are co-marketing Eliquis, while both companies are noted as dividend payers.